Arlyss
Well-known member
This month (August 2007) a paper has been published that brings together in one summary very important information for families where a BAV has been found.
If anyone has difficulty justifying screening and ongoing monitoring of ALL family members, including insurance authorizations, this paper provides justification for doing it. (Other papers have reported also, but the key points are all covered in this one paper.)
It describes 13 families that were selected for study because one member had a BAV and TAA (Thoracic Aortic Aneurysm).
Since this is a genetically based study, it also found that it may be carried and passed on by someone not obviously affected themself.
Here is the link to this paper
http://www.ncbi.nlm.nih.gov/sites/e...ez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
In all 13 families, one or more people had TAA without an obvious BAV.
In 11 out of 13 families, the greatest enlargement was in the ascending aorta ("above the sinotubular junction"). This is a hallmark of BAVD versus other syndromes - and can be dangerous in terms of missing the aneurysm when echo is used to screen. The ascending aorta (not the "root") is where the greatest danger lurks for BAVD.
They state that "BAV and TAA are independent manifestations of a single gene defect".
Also quoting from the abstract:
"To avoid the risk of early death, it is essential that all first-degree relatives receive echocardiographic follow-up at regular intervals regardless of the presence or absence of a BAV. This assessment must include imaging of the aortic region above the STJ."
Once a BAV is found, every family member becomes suspect. They may or may not have an obviously defective valve, but the aneurysm may be there, in the ascending aorta. If an echo does not "look" high enough, above the root, and "see" the ascending aorta, the enlargement/aneurysm will be missed. An MRI or CT with contrast will show the entire aorta. The requirement to see the aorta above the STJ (sinotubular junction) justifies the cost of MRI and CT in these individuals.
This paper builds on the timeline of information about BAVD (BAV/TAA) first reported in the medical literature in 1928, 1952, and 1972. As genetic analysis confirms what families have been experiencing all along, it should give them support to get the proactive screening and follow up they need. Notice it is not just a "one time" screening, but "follow-up at regular intervals". This condition "progresses" with time.
Best wishes,
Arlyss
If anyone has difficulty justifying screening and ongoing monitoring of ALL family members, including insurance authorizations, this paper provides justification for doing it. (Other papers have reported also, but the key points are all covered in this one paper.)
It describes 13 families that were selected for study because one member had a BAV and TAA (Thoracic Aortic Aneurysm).
Since this is a genetically based study, it also found that it may be carried and passed on by someone not obviously affected themself.
Here is the link to this paper
http://www.ncbi.nlm.nih.gov/sites/e...ez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
In all 13 families, one or more people had TAA without an obvious BAV.
In 11 out of 13 families, the greatest enlargement was in the ascending aorta ("above the sinotubular junction"). This is a hallmark of BAVD versus other syndromes - and can be dangerous in terms of missing the aneurysm when echo is used to screen. The ascending aorta (not the "root") is where the greatest danger lurks for BAVD.
They state that "BAV and TAA are independent manifestations of a single gene defect".
Also quoting from the abstract:
"To avoid the risk of early death, it is essential that all first-degree relatives receive echocardiographic follow-up at regular intervals regardless of the presence or absence of a BAV. This assessment must include imaging of the aortic region above the STJ."
Once a BAV is found, every family member becomes suspect. They may or may not have an obviously defective valve, but the aneurysm may be there, in the ascending aorta. If an echo does not "look" high enough, above the root, and "see" the ascending aorta, the enlargement/aneurysm will be missed. An MRI or CT with contrast will show the entire aorta. The requirement to see the aorta above the STJ (sinotubular junction) justifies the cost of MRI and CT in these individuals.
This paper builds on the timeline of information about BAVD (BAV/TAA) first reported in the medical literature in 1928, 1952, and 1972. As genetic analysis confirms what families have been experiencing all along, it should give them support to get the proactive screening and follow up they need. Notice it is not just a "one time" screening, but "follow-up at regular intervals". This condition "progresses" with time.
Best wishes,
Arlyss